Patent EP0214735A1 successfully refreshed from Google Patents.
EP0214735A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Controlled release pharmaceutical composition
Assignee: Euro Celtique SA
•
Filing: 1986-07-24
•
Granted: —
•
Expires: 2006-07-24
Abstract
Abstract A solid, controlled release, pharmaceutical composition comprising a drug and an anionic surfactant, incorporated in a matrix comprising a hydrophilic polymer, wherein the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that,. the organic base is not propranolol or chlorpheniramine. Preferably the drug is an acid addition salt of an organic amine, the surfactant is a sulphosuccinate and the polymer is a water-soluble hydroxyalkyl cellulose ether.
Inventors
- 👤 Rosa Martani
- 👤 Elisabeth Le Huede
- 👤 Jeanne Dumas
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 08:48
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K9/2013
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
51 words
A solid, controlled release pharmaceutical composition comprising a drug and an anionic surfactant, incorporated in a matrix comprising a hydrophilic polymer, characterised in that the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that, the organic base is not propranolol or chlorpheniramine.
Claim 2
Dependent Claim
51 words
A solid, controlled release pharmaceutical composition comprising a drug and an anionic surfactant, incorporated in a matrix comprising a hydrophilic polymer, characterised in that the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that, the organic base is not propranolol or chlorpheniramine.
Claim 3
Dependent Claim
29 words
A composition according to claim 1 characterised in that the drug is an acid addition salt of an organic base, preferably the acid addition salt of an organic amine.
Claim 4
Dependent Claim
64 words
A composition according to either claim 1 or claim 2, characterised in that the drug is selected from acid addition salts of metoclopramide, codeine, ethylmorphine, morphine, dextromethorphan, quinidine, quinine, dihydrocodeine, hydromorphone, perphenazine, diltiazem, meptazinol and flupirfine, especially metoclopramide hydrochloride, codeine phosphate, ethylmorphine hydrochloride, morphine sulphate, dextromethorphan hydrobromide, quinidine polygalacturonate, quinine sulphate, dihydrocodeine tartrate, hydromorphone hydrochloride, perphenazine hydrochloride, diltiazem hydrochloride, meptazinol hydrochloride and flupirtine maleate.
Claim 5
Dependent Claim
25 words
A composition according to any one of claims 1 to 3 characterised in that the anionic surfactant comprises a sulphonate surfactant, especially a sulphosuccinate surfactant.
Claim 6
Dependent Claim
23 words
A composition according to claim 4 characterised in that the anionic surfactant comprises a dialkyl sulphosuccinate surfactant, especially dioctyl sulphosuccinate, alkali metal salt.
Claim 7
Dependent Claim
29 words
A composition according to any one of claims 1 to 5 characterised in that the hydrophilic polymer comprises a water soluble, nonionic cellulose ether, especially a hydroxyalkyl cellulose ether.
Claim 8
Dependent Claim
38 words
A composition according to any one of claims 1 to 6 characterised in that the total weight of the hydrophilic polymer and the anionic surfactant in the composition is between 10% and 60%, especially between 10% and 50%.
Claim 9
Dependent Claim
42 words
A composition according to any one of claims 1 to 7 characterised in that the composition is in the form of a unit dose and the unit dose contains between 1 and 30mg, preferably between 2 and 20mg, of the anionic surfactant.
Claim 10
Dependent Claim
65 words
A process for the preparation of a solid, controlled release, pharmaceutical unit dosage form comprising granulating a composition comprising a drug, a hydrophilic polymer and an anionic surfactant and, optionally, compressing and shaping the. granules characterised in that the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that, the organic base is not propranolol or chlorpheniramine.
Claim 11
Dependent Claim
65 words
A process for the preparation of a solid, controlled release, pharmaceutical unit dosage form comprising granulating a composition comprising a drug, a hydrophilic polymer and an anionic surfactant and, optionally, compressing and shaping the. granules characterised in that the drug is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that, the organic base is not propranolol or chlorpheniramine.
Claim 12
Dependent Claim
56 words
A complex between an anionic surfactant and a drug which is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that. the organic base is not propranolol or chlorpheniramine wherein the rate of drug release from the complex, when the complex is incorporated in a hydrophilic polymer matrix, is controlled.
Claim 13
Dependent Claim
56 words
A complex between an anionic surfactant and a drug which is either an acid addition salt of an organic base or a quaternary ammonium salt, provided that. the organic base is not propranolol or chlorpheniramine wherein the rate of drug release from the complex, when the complex is incorporated in a hydrophilic polymer matrix, is controlled.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.